Infliximab (Revellex) inflammatory bowel disease: guidelines
| Autor: | J Garisch, H Schneider, JP Wright, C Ziady, C Kassianides |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2004 |
| Předmět: |
medicine.medical_specialty
Hepatology medicine.diagnostic_test business.industry medicine.medical_treatment Gastroenterology Human immunodeficiency virus (HIV) Colonoscopy Enema Disease medicine.disease_cause medicine.disease Inflammatory bowel disease digestive system diseases Infliximab Acquired immunodeficiency syndrome (AIDS) Pulmonary tuberculosis Internal medicine medicine business medicine.drug |
| Zdroj: | South African Gastroenterology Review; Vol 1, No 1 (2003); 18-18 |
| ISSN: | 1812-1659 |
| Popis: | Extracted from text ... SAGES GUIDELINES The South African Gastroenterology Review - August 2003 18 Infliximab (Revellex) inflammatory bowel disease protein that is in the antibody. There is also a serious risk of re-activating pulmonary tuberculosis. The prognosis is very poor in these patients, especially when aggravated by HIV/ Aids. Guidelines for the use of Infliximab (Revellex) 1 The patient should be managed by a registered gastroenterologist. 2 The diagnosis of Crohn's Disease must be confirmed with recent small bowel enema, colonoscopy, histology and raised acute phase reactants. The exact combination of criteria would depend on the disease localization and the type of .. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|